INTRODUCTION
============

Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer worldwide, with about 750,000 patients reported globally each year (International Agency for Research on Cancer, website: <http://globocan.iarc.fr>). Poor survival of HCC patients has several causes, frequently including resistance to chemotherapy. Many ATP-binding cassette (ABC) transporter family members can decrease the intracellular concentration of toxic compounds ([@B1]; [@B7]; [@B18]; [@B7]; [@B11]). These transmembrane pumps are over-expressed in tumor cells, hence causing the multidrug resistance phenotype. ABCB1 and ABCC3 have been shown to be up-regulated in HCC ([@B6]; [@B15]) and the up-regulation of ABCC1 has been associated with a more aggressive HCC phenotype ([@B19]). Thus far ABCB1 inhibitors have failed to show benefit during clinical trials, but more are being tested ([@B10]). Decreasing the expression of other ABC transporters is a desirable alternative as it could potentially reverse the multidrug resistance phenotype.

RNA interference (RNAi) is an attractive approach to achieve this goal, as it would allow combinatorial, possibly patient-tailored targeting of ABC transporters. RNAi is a naturally-occurring post-transcriptional gene silencing mechanism, which can induce sequence-specific degradation of a messenger RNA (mRNA), thus reducing gene expression. RNAi can be induced by synthetic small interfering RNAs (siRNAs), or by intracellular expression of short hairpin RNAs (shRNAs) and artificial microRNAs (miRNAs). shRNAs and miRNAs are processed by Dicer into siRNAs, which are loaded onto the RNA-induced silencing complex (RISC), where they mediate sequence-specific mRNA recognition, ultimately causing its degradation. *In vivo* siRNA-mediated knock-down of *Abbc1* has been demonstrated after intratumoral siRNA injection followed by *in situ* electroporation of the tumor; this led to a reduction in tumor weight in response to epirubicin ([@B20]). In addition, *Abbc2* was inhibited *in vitro* and *in vivo* by plasmid-, adenovirus- and lentivirus-delivered shRNAs, which respectively resulted in reversed cisplatin and paclitaxel resistance ([@B12]), decreased bilirubin transport ([@B16]), and reduced growth of cisplatin-treated tumors ([@B21]). Despite these findings, the major problem of RNAi applications still lies in sustained and tissue-specific delivery of the effector molecules *in vivo*. Recombinant adeno-associated virus (AAV) has emerged as the vector of choice for gene therapy and for RNAi-mediated therapy, as it yields long-term, tissue-specific expression without any apparent pathogenicity ([@B2]). In the current study we assessed the feasibility of *in vivo* AAV-mediated knock-down of two murine endogenous ABC transporters: ABCC1 and ABCC2. Initially, we verified the knock-down activity of 13 shRNA constructs and selected two candidates targeting *Abbc2* for further *in vivo* testing. A single injection of self-complementary AAV8 (scAAV8) carrying shAbcc2 resulted in efficient *Abbc2* knock-down in murine liver. Concomitant signs of toxicity including elevated transaminases were attributed to high levels of shRNAs being processed into siRNAs, causing oversaturation of the RNAi machinery. Nevertheless, subsequent translocation of the validated shRNA sequences into a miRNA scaffold offers the perspective of safe AAV-mediated *in vivo* knock-down.

MATERIALS AND METHODS
=====================

DNA constructs
--------------

Six shRNA constructs targeting murine *Abbc1* and seven targeting murine *Abbc2*, and control shRNAs targeting eGFP (shGFP) and Luciferase (shLuc) and a scramble sequence (shScr) were made by annealing of complementary oligonucleotides and ligating them into the pSuper vector containing the H1 Pol III promoter (OligoEngine, Seattle, WA). The sequence for constructing the negative control hairpin shScr has been described previously ([@B3]). The sequences of oligonucleotides used in this study are listed in [Table 1](#T1){ref-type="table"}. Luciferase reporters *Luc-Abbc11/17* and *Abbc22/28* were made by cloning of *Abbc1/2* sequences behind renilla luciferase in the siCheck vector (Promega, Madison, WI).

###### 

Oligonucleotide sequences used in this study. mmu-*Abcc1* (NM_008576), mmu-*Abcc2* (NM_013806), *luc* and *gfp* sequences in the shRNA oligos are in bold.

  Name           Sequence (5′--3′)                                                                                           Target         
  -------------- ----------------------------------------------------------------------------------------------------------- -------------- ------------
  shAbcc11-f     GATCCCCGATGACACACCTCAACAAATTCAAGAGATTTGTTGAGGTGTGTCATCTTTTTA                                                Abcc1          207--225
  shAbcc11-r     TCGAGAAAAAGATGACACACCTCAACAAATCTCTTGAATTTGTTGAGGTGTGTCATCGGG                                                               
  shAbcc12-f     GATCCCCTTACTACAAGGCAGTTATGTTCAAGAGACATAACTGCCTTGTAGTAATTTTTA                                                Abcc1          2214--2232
  shAbcc12-r     TCGAGAAAAATTACTACAAGGCAGTTATGTCTCTTGAACATAACTGCCTTGTAGTAAGGG                                                               
  shAbcc15-f     GATCCCCTCTACTTCTTCTATCTCTCTTCAAGAGAGAGAGATAGAAGAAGTAGATTTTTA                                                Abcc1          169--182
  shAbcc15-r     TCGAGAAAAATCTACTTCTTCTATCTCTCTCTCTTGAAGAGAGATAGAAGAAGTAGAGGG                                                               
  shAbcc16-f     GATCCCCTGTTCAATATCTTGCGCTTTTCAAGAGAAAGCGCAAGATATTGAACATTTTTA                                                Abcc1          1175--1793
  shAbcc16-r     TCGAGAAAAATGTTCAATATCTTGCGCTTTCTCTTGAAAAGCGCAAGATATTGAACAGGG                                                               
  shAbcc17-f     GATCCCCGAAGCTAATGGAAGCAGACTTCAAGAGAGTCTGCTTCCATTAGCTTCTTTTTA                                                Abcc1          2832--2850
  shAbcc17-r     TCGAGAAAAAGAAGCTAATGGAAGCAGACTCTCTTGAAGTCTGCTTCCATTAGCTTCGGG                                                               
  shAbcc18-f     GATCCCCCCTGGACCTGCTATACAATTTCAAGAGAATTGTATAGCAGGTCCAGGTTTTTA                                                Abcc1          3147--3165
  shAbcc18-r     TCGAGAAAAACCTGGACCTGCTATACAATTCTCTTGAAATTGTATAGCAGGTCCAGGGGG                                                               
  shAbcc22-f     GATCCCCCTTGGCTAGGAGGCAGTACTTCAAGAGAGTACTGCCTCCTAGCCAAGTTTTTA                                                Abcc2          1221--1239
  shAbcc22-r     TCGAGAAAAACTTGGCTAGGAGGCAGTACTCTCTTGAAGTACTGCCTCCTAGCCAAGGGG                                                               
  shAbcc23-f     GATCCCCCCATGTTCTGGATTCTCTCTTCAAGAGAGAGAGAATCCAGAACATGGTTTTTA                                                Abcc2          395--413
  shAbcc23-r     TCGAGAAAAACCATGTTCTGGATTCTCTCTCTCTTGAAGAGAGAATCCAGAACATGGGGG                                                               
  shAbcc24-f     GATCCCCTGACCAACTACTACACTTTTCAAGAGAAAGTGTAGTAGTTGGTCATTTTTA                                                  Abcc2          1295--1313
  shAbcc24-r     TCGAGAAAAATGACCAACTACTACACTTTCTCTTGAAAAGTGTAGTAGTTGGTCAGGG                                                                 
  shAbcc25-f     GATCCCCCATCTATATTCTAGACGACTTCAAGAGAGTCGTCTAGAATATAGATGTTTTTA                                                Abcc2          2334--2352
  shAbcc25-r     TCGAGAAAAACATCTATATTCTAGACGACTCTCTTGAAGTCGTCTAGAATATAGATGGGG                                                               
  shAbcc26-f     GATCCCCTTACTTGTAACATCAAGAGTTCAAGAGACTCTTGATGTTACAAGTAATTTTTA                                                Abcc2          3953--3971
  shAbcc26-r     TCGAGAAAAATTACTTGTAACATCAAGAGTCTCTTGAACTCTTGATGTTACAAGTAAGGG                                                               
  shAbcc27-f     GATCCCCATACTGGACAAGCCACAATTTCAAGAGAATTGTGGCTTGTCCAGTATTTTTTA                                                Abcc2          266--284
  shAbcc27-r     TCGAGAAAAAATACTGGACAAGCCACAATTCTCTTGAAATTGTGGCTTGTCCAGTATGGG                                                               
  shAbcc28-f     GATCCCCTCTCTACCTATGCACTTGGTTCAAGAGACCAAGTGCATAGGTAGAGATTTTTA                                                Abcc2          312--330
  shAbcc28-r     TCGAGAAAAATCTCTACCTATGCACTTGGTCTCTTGAACCAAGTGCATAGGTAGAGAGGG                                                               
  shScr-f        GATCCCCGATCGAATGTGTACTTCGATTCCAAGAGATCGAAGTACACATTCGATCTTTTTGCATGCC                                         Doege et al.   2008
  shScr-r        TCGAGGCATGCAAAAAGATCGAATGTGTACTTCGATCTCTTGGAATCGAAGTACACATTCGATCGGG                                                        
  shGFP-f        GATCCCCAGCTGGAGTACAACTACAACCTTCCTGTCAGTTGTAGTTGTACTCCAGCTTTTTGCATGCC                                        eGFP           
  shGFP-r        TCGAGGCATGCAAAAAGCTGGAGTACAACTACAACTGACAGGAAGGTTGTAGTTGTACTCCAGCTGGG                                                       
  shLuc-M-f      GATCCCCCTGCCCTGCTGGTGCCCACACTTCCAAGAGAGTGTGGGCACCAGCAGGGCAGTTTTTGCATGCC                                     Luc            
  shLuc-M-r      TCGAGGCATGCAAAAACTGCCCTGCTGGTGCCCACACTCTCTTGGAAGTGTGGGCACCAGCAGGGCAGGGG                                                    
  Luc-Abcc11-f   TCGAGTCTCTCTCGCCATGACCGGGGCTACATCCAGATGACACACCTCAACAAAACCAAAACTGCCTTAGGATTCTTTCTGC                          Abcc11         
  Luc-Abcc11-r   GGCCGCAGAAAGAATCCTAAGGCAGTTTTGGTTTTGTTGAGGTGTGTCATCTGGATGTAGCCCCGGTCATGGCGAGAGAGAC                                         
  Luc-Abcc17-f   TCGAGGCAGAAGGCTGGAGCTAAGGAGGAGACGTGGAAGCTAATGGAAGCAGACAAGGCCCAGACAGGGCAGGTGCAGCTGC                          Abcc17         
  Luc-Abcc17-r   GGCCGCAGCTGCACCTGCCCTGTCTGGGCCTTGTCTGCTTCCATTAGCTTCCACGTCTCCTCCTTAGCTCCAGCCTTCTGCC                                         
  Luc-Abcc22-f   TCGAGTATATAAGAAGGCACTAACCCTATCTAACTTGGCTAGGAGGCAGTACACGATTGGAGAGACGGTGAACTTGATGC                            Abcc22         
  Luc-Abcc22-r   GGCCGCATCAAGTTCACCGTCTCTCCAATCGTGTACTGCCTCCTAGCCAAGTTAGATAGGGTTAGTGCCTTCTTATATAC                                           
  Luc-Abcc28-f   TCGAGACCTCTCACAGAAGATACTGGACAAGCCACAATTCCTCCTGTTAAATATACAAATCCAATTCTCTACCTATGCACTTGGCTCCTGGTGTTGGTGGCAGGC   Abcc28         
  Luc-Abcc28-r   GGCCGCCTGCCACCAACACCAGGAGCCAAGTGCATAGGTAGAGAATTGGATTTGTATATTTAACAGGAGGAATTGTGGCTTGTCCAGTATCTTCTGTGAGAGGTC                  
  Abcc1-f        GAGTCAAAGCCGGTGGAAAAT                                                                                       Abcc1          qRT-PCR
  Abcc1-r        TTAGCTCCAGCCTTCTGCAGTT                                                                                                     
  Abcc2-f        TGAAAAACAGAATGGGACCGA                                                                                       Abcc2          qRT-PCR
  Abcc2-r        TTGGATGCATTTCTGCAAGC                                                                                                       
  Actin-f        ACGGCCAGGTCATCACTATTG                                                                                       βactin         qRT-PCR
  Actin-r        CAAGAAGGAAGGCTGGAAAAGA                                                                                                     
  Gapdh-f        ACATGTTCCAGTATGACTCCACTCA                                                                                   Gapdh          qRT-PCR
  Gapdh-r        GCCTCACCCCATTTGATGTT                                                                                                       
  Hprt-f         AAGACTTGCTCGAGATGTCATGAAG                                                                                   Hprt           qRT-PCR
  Hprt-r         TCCAGCAGGTCAGCAAAGAA                                                                                                       
  Ifnb1-f        CTGCCTTTGCCATCCAAGAG                                                                                        Ifnb1          qRT-PCR
  Ifnb1-r        ACTGTCTGCTGGTGGAGTTC                                                                                                       
  Igs56-f        TGCACAACCTCCTGGCCTAC                                                                                        Isg56          qRT-PCR
  Igs56-r        TCGCCAGGCTTCTCTTGCTC                                                                                                       
  Oas1b-f        TGATGTGCTGCCAGCCTATG                                                                                        Oasb1b         qRT-PCR
  Oas1b-r        GATAACTTGCCCTCCTTCCC                                                                                                       
  Stat1-f        GTGAGAGCCAGTCGTTTCAG                                                                                        Stat1          qRT-PCR
  Stat1-r        GCAGGTTCGGGATTCAACAC                                                                                                       
  LP1-f          CCCTGTTTGCTCCTCCGATAA                                                                                       LP1            qRT-PCR
  LP1-r          GTCCGTATTTAAGCAGTGGATCCA                                                                                                   

For cloning in the AAV backbone, the H1-shRNA expression cassettes were subcloned in pCR-Blunt II-TOPO vector (Invitrogen, Carlsbad, CA), and then ligated in the pVD287 vector. pVD287 contains the *egfp* gene under the control of the liver-specific LP-1 promoter and generates scAAV due to a mutation in one terminal repeat ([@B14]).

Cell culture and transfections
------------------------------

Human embryonic kidney (HEK) 293T and murine hepatoma (Hepa1-6) cell lines were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM, Invitrogen) containing 10% (v/v) fetal calf serum, 100U/ml penicillin and 100U/ml streptomycin, at 37°C and 5% (v/v) CO2. Cells were plated in 6-, 24- or 96-well plates one day prior to transfection. Transfections were performed with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer\'s instructions. For the interferon response experiment we transfected 2μg of a synthetic analog of dsRNA, polyinosinic:polycytidylic acid (poly I:C), as a positive control.

Luciferase assays
-----------------

For luciferase assays, cells were co-transfected with 10ng *Luc-Abbc* reporter that contains both firefly and renilla luciferase genes, and 0, 0.5, 2.5, 10 or 50ng of the corresponding shAbcc expression construct. Transfected cells were assayed at 48hr post-transfection and firefly and renilla luciferase were measured with the Dual-Luciferase Reporter Assay System (Promega). Relative luciferase activity was calculated as the ratio between the renilla and firefly luciferase activities, and transfection with shScr was set at 100%. Data are represented as mean values ±SD from a representative experiment conducted with three technical replicates.

RNA isolation, quantitative RT-PCR (RT-qPCR), siRNA and miRNA Taqman assays
---------------------------------------------------------------------------

For *in vitro* experiments, total RNA was isolated from cells 18hr or 72hr post-transfection using the Nucleospin kit (Clontech, Mountain View, CA). For *in vivo* experiments, total RNA was isolated from frozen liver sections at two weeks post-injection (p.i.) using Trizol (Invitrogen) according to the manufacturer\'s protocol. DNAse-treatment and RT-qPCR were performed as described previously ([@B9]) and data are represented as mean values ±SD from a representative experiment conducted with three technical replicates. siRNA and miRNA expression was quantified with custom-made siRNA assays or miRNA-specific Taqman assays (Applied Biosystems, Foster City, CA) according to manufacturer\'s instructions.

AAV vector production and in vivo experiments
---------------------------------------------

Self-complementary AAV8 vectors were produced and purified as previously described ([@B22]; [@B4]; [@B9]) with an added fractionation step yielding higher virus concentration. Final concentration was determined by qPCR with LP1 primers. All animal experiments were conducted according to the guidelines of the local animal welfare committee. Six-to-eight-week-old male C57BL/6 mice received 2.2×10^11^gc AAV-shScr, 2.6--3×10^12^gc AAV-shAbcc22 or -shAbcc28 per animal intravenously via the tail vein. Heparinized blood samples were taken by retro-orbital bleeding at 1 and 2 weeks p.i. for plasma analysis. Mice were sacrificed on day 15 p.i. and livers were examined for *Abbc1* and *Abbc2* knock-down. Plasma levels of alanine aminotransferase (ALT), aspartate amino-transferase (AST) and total bilirubin were analyzed on Modular Analytics P800 analyzer (Roche Diagnostics, Basel, Switzerland). Data are represented as mean values ±SEM (n = 4−5).

RESULTS AND DISCUSSION
======================

Design and validation of shRNAs targeting murine Abcc1 and Abcc2
----------------------------------------------------------------

Six shRNAs were designed against murine *Abcc1* mRNA (shAbcc11-shAbcc17) ([Figure 1A](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}), and seven against murine *Abcc2* mRNA (shAbcc22-shAbcc28) ([Figure 1B](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). The ability of these constructs to knock-down endogenous *Abcc1* and *Abcc2* was assessed *in vitro* in Hepa1--6 cells using shGFP and shLuc as negative controls. shAbcc11, shAbcc17, and all 7 shAbcc2 constructs, respectively inhibited endogenous *Abcc1* and *Abcc2* expression by more than 50% ([Figure 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}). For each target we selected the 2 most efficient shRNAs: shAbcc11 and shAbcc17, shAbcc22 and shAbcc28.

![shRNAs design and *in vitro* studies on endogenous *Abcc* mRNA and *Abcc* luciferase reporters. Schematic representation of *Abcc1* and *Abcc2* mRNA and target sequences of the shRNAs. **(A)** shAbcc11, shAbcc12, shAbcc15, shAbcc16, shAbcc17, shAbcc18 targeting *Abcc1* mRNA (NM_013806.2) and **(B)** shAbcc22, shAbcc23, shAbcc24, shAbcc25, shAbcc26, shAbcc27, shAbcc28 targeting *Abcc2* mRNA (NM_008576.2). Predicted stem-loop structure with guide strand in red of **(C)** shAbcc1 and **(D)** shAbcc2. **(E)** Endogenous *Abcc1* mRNA knock-down by shAbcc1 constructs and **(F)** endogenous *Abcc2* mRNA knock-down by shAbcc2 constructs in Hepa1--6 cells (shGFP-treated cells were set at 100%). **(G)** *Luc-Abcc1* and *Luc-Abcc2* knock-down by shAbcc1 and shAbcc2 constructs in HEK293T cells (shScr-treated cells were set at 100%). Relative amount of siRNA molecules after transfection of HEK293T **(H)** and Hepa1--6 cells **(I)** with shAbcc22, shAbcc28 and shApoB (the highest siApoB value was set at 100%).](jrgs-07-434-g001){#F1}

The specificity of *Abcc1* and *Abcc2* knock-down by these 4 constructs was tested on luciferase reporters containing the *Abcc1* or *Abcc2* target sequences. For all 4 constructs increasing concentrations of the shRNA construct induced dose-dependent inhibition of the specific luciferase reporter ([Figure 1G](#F1){ref-type="fig"}). These results support the sequence-specificity of endogenous *Abcc1* and *Abcc2* knock-down by these shRNAs.

siRNA processing was examined *in vitro* in two cell lines and was compared with the siRNA processing of a validated active shRNA, shApoB ([@B9]). Efficient processing of the shRNA would indicate efficacy of the shRNA *in vivo*. HEK293T and Hepa1--6 cells were transfected with increasing amounts of plasmids encoding shAbcc22, shAbcc28 and shApoB. All shRNAs expressed similar amounts of siRNAs in HEK293T ([Figure 1H](#F1){ref-type="fig"}) and Hepa1--6 cells ([Figure 1I](#F1){ref-type="fig"}), indicating that they do not suffer from any misprocessing that could impair the anticipated *in vivo* knock-down.

Double-stranded RNA (dsRNA), including siRNAs, can induce the interferon response ([@B17]). We determined that none of the 4 selected shRNAs induced expression of marker genes of the interferon response *in vitro* following transfection of Hepa1--6 cells ([Figure 2](#F2){ref-type="fig"}).

![Four interferon pathway genes are not activated by the shAbcc constructs. Expression of interferon pathway genes. **(A)** Interferon beta 1 (*Ifnb1*), **(B)** Interferon-stimulated gene 56 (*Isg56*), **(C)** 2′-5′ oligoadenylate synthetase 1B (*Oasb1b*), **(D)** Signal transducer and activator of transcription 1 (*Stat1*). Gene expression was quantified by RT-qPCR and normalized to *β-Actin* expression (pSuper was set at 1).](jrgs-07-434-g002){#F2}

In vivo knock-down of Abcc1 and Abcc2 via scAAV-delivered shRNAs
----------------------------------------------------------------

C57BL/6 mice were injected with 4×1012gc/kg scAAV8 encoding shAbcc11, shAbcc17, shAbcc22, shAbcc28 and the shScr and PBS as controls. Animals were sacrificed at two weeks p.i. and *Abcc1*, *Abcc2* knock-down and siRNA expression in liver was determined, as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in plasma and interferon pathway genes expression in white blood cells. Transduction efficiency by scAAV8-shAbcc was greater than 90% as determined by fluorescence microscopy (data not shown). However, *Abcc1* and *Abcc2* mRNA expression was not affected significantly, and we could determine only very low levels of siRNA (data not shown). We concluded that at this viral dose, these shRNAs were not expressed at a level sufficient to show a detectable effect. We subsequently narrowed our focus on the highly-expressed *Abcc2* gene and injected C57 BL/6 mice with a 10--30 fold higher dose of 1.2--1.3x1014gc/kg AAV-shAbcc22, AAV-shAbcc28, and AAV-shScr and PBS as controls. Mice injected with AAV-shAbcc22 and AAV-shAbcc28 were therefore sacrificed on day-13p.i. in agreement with the guidelines of the local animal welfare committee as the animals presented some signs of physiological stress and one AAV-shAbcc22-injected mouse died. Animals from AAV-shScr and PBS groups were sacrificed on day-15p.i. Gene expression analysis by RT-qPCR in the livers revealed a profound knock-down of *Abcc2* mRNA up to 83% by shAbcc22 and shAbcc28 ([Figure 3A](#F3){ref-type="fig"}). Since there were signs of toxicity, we determined whether the *Abcc2* knock-down was sequence-specific rather than due to general toxicity. Therefore, the expression of the housekeeping genes, *β-Actin*, glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) and hypoxanthine guanine phosphoribosyl transferase (*Hprt*), was determined in RNA isolated from mouse livers. Our results indicated no detectable down-regulation of expression of the housekeeping genes between the 3 AAV-injected groups (data not shown), thus indicating the sequence-specificity of *Abcc2* knock-down by AAV-shAbcc22 and AAV-Abcc28 *in vivo*. Further quantification of the amount of siAbcc22 and siAbcc28 by Taqman revealed a higher number of siRNA in the AAV-shAbcc22-injected mice than in the AAV-shAbcc28-injected mice ([Figure 3B](#F3){ref-type="fig"}).

![*In vivo* knock-down of *Abcc2* and quantification of siAbcc2. **(A)** Relative *Abcc2* expression was quantified by RT-qPCR and normalized to *β-Actin* (shScr group was set at 100%). **(B)** Relative expression of siAbcc22 and siAbcc28 molecules was quantified by RT-qPCR and normalized to *β-Actin* expression (the highest value was set at 100%).](jrgs-07-434-g003){#F3}

Interestingly, the mouse injected with AAV-shAbcc22, which first showed signs of toxicity and died was indeed the one presenting the highest levels of siRNA. While *in vitro* the amount siRNA produced by shAbcc22 and shAbcc28 was similar, *in vivo* there were differences between mice injected with the same dose of AAV-shAbcc22 and AAV-shAbcc28. We conclude that our *in vitro* studies were insufficient predictors of the shRNAs processing *in vivo*. Nevertheless, *in vitro* efficacy correlated well with *in vivo* results, which, following highly-efficient transduction of hepatocytes with AAV8, achieved 83% knock-down of the target mRNA.

During the first week p.i. the mice from the AAV-shAbcc22 and AAV-shAbcc28 groups did not gain any weight, while the AAV-shScr and the PBS groups did (data not shown). It appears that the over-expression of shAbcc22 and shAbcc28 *in vivo* resulted in severe toxicity. Mice presented several indications of physiological stress. Analysis of plasma sampled on day-8p.i. revealed elevated levels of AST, ALT and total bilirubin indicating liver toxicity in the AAV-shAbcc groups ([Figure 4A](#F4){ref-type="fig"}). On day-13p.i. one of the AAV-shAbcc22-injected mice died and subsequently all mice from both AAV-shAbcc22 and AAV-shAbcc28 groups were sacrificed on the same day. Plasma analysis at two weeks p.i. revealed highly-elevated AST and ALT levels in the AAV-shScr group (data not shown), and weight loss was also observed during the second week p.i., indicating a slower onset of the toxicity, most likely due to the lower viral dose that was administered to this group.

![Overexpression of shAbcc2 induces liver toxicity. **(A)** Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in plasma at 8-days p.i. **(B)** Relative expression of three cellular miRNAs, miR-122, miR-29a and let-7a was quantified by RT-qPCR and normalized to *β-Actin* expression (PBS group was set at 100%).](jrgs-07-434-g004){#F4}

It has been reported that high siRNA expression from shRNA cassettes containing a strong promoter can lead to lethal toxicity by over-saturating the RNAi machinery and affecting endogenous miRNA processing ([@B3]). We determined the expression levels of 3 cellular miRNAs, namely miR-122, miR-29a and let-7a, in the livers of the injected animals. If saturation of the RNAi machinery occurred to the point where endogenous metabolic processes are expected to be significantly affected, expression of these liver miRNAs should be significantly decreased. Taqman assays for the 3 cellular miRNAs revealed down-regulation in the mouse livers injected with AAV-shScr, AAV-shAbcc22 and AAV-shAbcc28 compared to the PBS group ([Figure 4B](#F4){ref-type="fig"}), indicating oversaturation of the RNAi machinery.

Circumventing shRNA toxicity
----------------------------

Expression of shRNA from a weaker promoter and from a miRNA scaffold can circumvent toxicity problems ([@B13]). Therefore, shAbcc11 and shAbcc28 sequences were expressed from a miRNA backbone ([Figure 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}) and their ability to knock-down *Luc-Abcc11* and *Luc-Abcc28* luciferase reporters was assessed *in vitro* in HEK293T cells. Comparison of knock-down induced by shAbcc11 and miAbcc11, and by shAbcc28 and miAbcc28 showed that both constructs had a similar efficiency -- the miRNA being slightly better ([Figure 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}). Furthermore, quantification of the amount of siRNA molecules necessary to achieve this knock-down effect by Taqman assay showed that miAbcc28 produced 55%-75% less siAbcc28 molecules than shAbcc28 ([Figure 5E](#F5){ref-type="fig"}). Since these miRNAs were expressed from a significantly weaker Pol II promoter, less siRNA molecules were apparently being produced while retaining equal inhibitory properties compared to the shRNA. This indicates that miRNAs may be more potent molecules for induction of RNA silencing than shRNAs. Considering the toxicity issues raised in this study the possibility of expressing siRNA sequences from a miRNA backbone, which would render similar or increased efficiency but would present reduced toxicity risks in *in vivo* studies is of considerable interest. We are currently comparing the long-term efficacy and toxicity profile of siRNAs expressed from AAV-shRNA and AAV-miRNA backbone *in vivo*. Future research will therefore focus on expressing siRNA from a miRNA backbone to achieve efficient and safe *in vivo* target knock-down.

![Expression of shAbcc11 and shAbcc28 from a miRNA scaffold and siRNA quantification. Predicted stem-loop structure with guide strand in red of **(A)** miAbcc11 and **(B)** miAbcc28. *Luc-Abcc1* knock-down by *Abcc1*-targeting **(C)** and *Luc-Abcc2* knock-down by *Abcc2*-targeting **(D)** shRNAs and miRNAs (shScr and miScr were set at 100%). **(E)** Relative amount of siRNA molecules produced by shRNA and miRNA constructs (the lowest shRNA dose was set at 100%).](jrgs-07-434-g005){#F5}

To our knowledge, this is the first report to show AAV-mediated knock-down of *Abcc2* *in vivo.* Concomitant toxicity was observed and was attributed to a previously described mechanism of oversaturation of the RNAi machinery ([@B3]). Subsequent generation of miRNAs showed a better efficacy profile, *i.e*., the same effect mediated by significantly less siRNA molecules. We therefore expect that these constructs will yield a strong and safe knock-down following liver transduction with AAV.

CONCLUSIONS
===========

-   Expression of multiple anti-*Abcc1* and anti-*Abcc2* shRNAs

-   *In vitro* studies are insufficient predictors of the shRNAs processing *in vivo*

-   Strong knock-down of *Abcc2* *in vivo* following AAV-shAbcc delivery

-   Concomitant toxicity due to oversaturation of the RNAi machinery

-   Toxicity can be circumvented by siRNA expression from a natural miRNA scaffold
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